REVascularisation for Ischaemic VEntricular Dysfunction

King's College London0 sites700 target enrollmentNovember 20, 2012

Overview

2018 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/29852933 protocol (added 19/11/2019) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36027563/ primary composite outcome of death from any cause or hospitalization for heart failure (added 22/12/2022)

Registry

who.int

Start Date

November 20, 2012

End Date

March 31, 2022

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

•Current inclusion criteria as of 13/08/2014:
•1\. LVEF \=35%
•2\. Extensive coronary disease (BCIS\-1 Jeopardy Score \=6\)
•3\. Viability in at least 4 dysfunctional segments, that can be revascularised by PCI
•Previous inclusion criteria:
•1\. LVEF \=30%
•2\. Extensive coronary disease (BCIS\-1 Jeopardy Score \=6\)
•3\. Viable myocardium in \=30% of dysfunctional segments

•Current exclusion criteria as of 14/09/2018:
•1\. Myocardial infarction \<4 weeks previously
•2\. Decompensated heart failure requiring inotropic support, invasive or non\-invasive ventilation or IABP/left ventricular assist device (LVAD) therapy \<72 hours prior to randomisation
•3\. Sustained VT/VF or appropriate ICD discharges \<72 hours prior to randomisation
•4\. Valve disease requiring intervention
•5\. Contraindications to PCI
•6\. Aged \<18 years
•7\. eGFR \< 25 ml/min, unless established on dialysis
•8\. Women who are pregnant
•9\. Previously enrolled in REVIVED\-BCIS2 or current enrolment in other trial that may affect REVIVED\-BCIS2 outcome data